FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3154399066> ?p ?o ?g. }

• W3154399066 endingPage "1964" @default.
• W3154399066 startingPage "1964" @default.
• W3154399066 abstract "Different peripheral blood parameters have emerged as prognostic biomarkers in breast cancer (BC), but their predictive role in Human Epidermal growth factor Receptor 2 positive (HER2+) advanced BC (aBC) patients receiving dual anti-HER2 blockade remains unclear. We evaluated the impact of the Pan-Immune-Inflammatory Value (PIV), defined as the product of peripheral blood neutrophil, platelet, and monocyte counts divided by lymphocyte counts, on the prognosis of HER2+ aBC patients treated with first line trastuzumab-pertuzumab-based biochemotherapy. We also evaluated the association between the neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), and the monocyte to lymphocyte ratio (MLR) and clinical outcomes. Cox regression models were used to estimate the impact of these variables, as well as of other clinically relevant covariates, on patient survival. We included 57 HER2+ aBC patients treated with taxane-trastuzumab-pertuzumab in our Institution. High baseline MLR, PLR, and PIV were similarly predictive of worse PFS at univariate analysis, but only high PIV was associated with a trend toward worse PFS at multivariable analysis. Regarding OS, both high PIV and MLR were associated with significantly worse patient survival at univariate analysis, but only the PIV was statistically significantly associated with worse overall survival at multivariable analysis (HR 7.96; 95% CI: 2.18–29.09). Our study reveals the PIV as a new and potent predictor of OS in HER2+ aBC patients treated with first line trastuzumab-pertuzumab-containing biochemotherapy. Prospective studies are needed to validate this new prognostic parameter in HER2+ aBC." @default.
• W3154399066 created "2021-04-26" @default.
• W3154399066 creator A5000073229 @default.
• W3154399066 creator A5004176474 @default.
• W3154399066 creator A5009450386 @default.
• W3154399066 creator A5009935310 @default.
• W3154399066 creator A5012144681 @default.
• W3154399066 creator A5013009758 @default.
• W3154399066 creator A5018257698 @default.
• W3154399066 creator A5020943144 @default.
• W3154399066 creator A5034079179 @default.
• W3154399066 creator A5039319350 @default.
• W3154399066 creator A5044355698 @default.
• W3154399066 creator A5081344507 @default.
• W3154399066 date "2021-04-19" @default.
• W3154399066 modified "2023-10-12" @default.
• W3154399066 title "The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab" @default.
• W3154399066 cites W1841839849 @default.
• W3154399066 cites W1870525143 @default.
• W3154399066 cites W1968519475 @default.
• W3154399066 cites W1971267920 @default.
• W3154399066 cites W1971422550 @default.
• W3154399066 cites W1982906652 @default.
• W3154399066 cites W2002157461 @default.
• W3154399066 cites W2006070721 @default.
• W3154399066 cites W2006908114 @default.
• W3154399066 cites W2029166421 @default.
• W3154399066 cites W2054016709 @default.
• W3154399066 cites W2067971776 @default.
• W3154399066 cites W2085458222 @default.
• W3154399066 cites W2095156669 @default.
• W3154399066 cites W2104239861 @default.
• W3154399066 cites W2105156168 @default.
• W3154399066 cites W2108929503 @default.
• W3154399066 cites W2112434826 @default.
• W3154399066 cites W2125885282 @default.
• W3154399066 cites W2131193892 @default.
• W3154399066 cites W2133105825 @default.
• W3154399066 cites W2137228442 @default.
• W3154399066 cites W2139135964 @default.
• W3154399066 cites W2141393790 @default.
• W3154399066 cites W2165003903 @default.
• W3154399066 cites W2166199281 @default.
• W3154399066 cites W2515477177 @default.
• W3154399066 cites W2559858344 @default.
• W3154399066 cites W2571423414 @default.
• W3154399066 cites W2621280624 @default.
• W3154399066 cites W2751382700 @default.
• W3154399066 cites W2801597117 @default.
• W3154399066 cites W2806428922 @default.
• W3154399066 cites W2889281172 @default.
• W3154399066 cites W2892951532 @default.
• W3154399066 cites W2921169442 @default.
• W3154399066 cites W2947477463 @default.
• W3154399066 cites W2996039207 @default.
• W3154399066 cites W3023859536 @default.
• W3154399066 cites W3024839384 @default.
• W3154399066 doi "https://doi.org/10.3390/cancers13081964" @default.
• W3154399066 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8073809" @default.
• W3154399066 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33921727" @default.
• W3154399066 hasPublicationYear "2021" @default.
• W3154399066 type Work @default.
• W3154399066 sameAs 3154399066 @default.
• W3154399066 citedByCount "36" @default.
• W3154399066 countsByYear W31543990662021 @default.
• W3154399066 countsByYear W31543990662022 @default.
• W3154399066 countsByYear W31543990662023 @default.
• W3154399066 crossrefType "journal-article" @default.
• W3154399066 hasAuthorship W3154399066A5000073229 @default.
• W3154399066 hasAuthorship W3154399066A5004176474 @default.
• W3154399066 hasAuthorship W3154399066A5009450386 @default.
• W3154399066 hasAuthorship W3154399066A5009935310 @default.
• W3154399066 hasAuthorship W3154399066A5012144681 @default.
• W3154399066 hasAuthorship W3154399066A5013009758 @default.
• W3154399066 hasAuthorship W3154399066A5018257698 @default.
• W3154399066 hasAuthorship W3154399066A5020943144 @default.
• W3154399066 hasAuthorship W3154399066A5034079179 @default.
• W3154399066 hasAuthorship W3154399066A5039319350 @default.
• W3154399066 hasAuthorship W3154399066A5044355698 @default.
• W3154399066 hasAuthorship W3154399066A5081344507 @default.
• W3154399066 hasBestOaLocation W31543990661 @default.
• W3154399066 hasConcept C121608353 @default.
• W3154399066 hasConcept C126322002 @default.
• W3154399066 hasConcept C143998085 @default.
• W3154399066 hasConcept C144301174 @default.
• W3154399066 hasConcept C2777511904 @default.
• W3154399066 hasConcept C2779786085 @default.
• W3154399066 hasConcept C2781164504 @default.
• W3154399066 hasConcept C38180746 @default.
• W3154399066 hasConcept C50382708 @default.
• W3154399066 hasConcept C530470458 @default.
• W3154399066 hasConcept C71924100 @default.
• W3154399066 hasConceptScore W3154399066C121608353 @default.
• W3154399066 hasConceptScore W3154399066C126322002 @default.
• W3154399066 hasConceptScore W3154399066C143998085 @default.
• W3154399066 hasConceptScore W3154399066C144301174 @default.
• W3154399066 hasConceptScore W3154399066C2777511904 @default.
• W3154399066 hasConceptScore W3154399066C2779786085 @default.

• next